These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29506546)

  • 21. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of malignant peritoneal mesothelioma: A population-based study.
    Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
    Cancer Epidemiol; 2017 Dec; 51():81-86. PubMed ID: 29080447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
    Liang Y; Li C; Liu Y; Tian L; Yang D
    BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal mesothelioma: the site of origin matters.
    Kindler HL
    Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival.
    Murphy S; Probert G; Anderson J; Pollock S; Taylor I; Clague H; Sridharan K
    Clin Oncol (R Coll Radiol); 2013 Dec; 25(12):713-8. PubMed ID: 24051173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
    Lee YK; Jun HJ; Nahm JH; Lim TS; Park JS; Ahn JB; Rha SY; Chung HC; Oh HE; Song JS; Yang WI; Kim HS
    Jpn J Clin Oncol; 2013 Oct; 43(10):996-1003. PubMed ID: 23964112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma].
    Wei F; Zheng GQ; Song H; Liang YF; Yin WJ; Sun NN; Yang YX
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 May; 38(5):321-326. PubMed ID: 32536066
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diffuse Malignant Peritoneal Mesothelioma with Secondary Liver Invasion Diagnosed Using Laparoscopy - A Case Report].
    Yasuda H; Okumura S; Toyoda S; Yamamoto K; Mizumura N; Itou A; Ogawa M; Kawasaki M; Kameyama M
    Gan To Kagaku Ryoho; 2018 Mar; 45(3):449-453. PubMed ID: 29650903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.
    Kobayashi S; Waragai T; Sano H; Mochizuki K; Akaihata M; Ohara Y; Hosoya M; Kikuta A
    Anticancer Drugs; 2014 Oct; 25(9):1102-5. PubMed ID: 25010395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
    Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
    J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    Liu D; Huang Y; Li L; Song J; Zhang L; Li W
    BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
    Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.